SAN CARLOS, Calif., April 19, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) (Iovance or the Company), a biotechnology company focused on innovating, developing, and...
Iovance Bio Announces FDA has Lifted Clinical Hold on the IOV-LUN-202
Iovance Biotherapeutics to Present at Upcoming Conferences
Around 12 days after winning an FDA thumbs up, Iovance Biotherapeutics’ advanced melanoma treatment Amtagvi has signed on 20 patients in what analysts describe as a promising launch.
Amtagvi„¢ (lifileucel) U.S. Launch Fully Underway Following U.S. Food and Drug Administration (FDA) Approval as the First and Only One-Time, Individualized T cell Therapy for a Solid Tumor Cancer ...
SAN CARLOS, Calif., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (NASDAQ: IOVA), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor...
SAN CARLOS, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Iovance Biotherapeutics, Inc. (Nasdaq: IOVA) (œIovance or œCompany), a biotechnology company focused on innovating, developing, and delivering...
WuXi Advanced Therapies (ATU) will manufacture Iovance’s recently approved Amtagvi for advanced melanoma, which was heralded as the first modern cell therapy to secure an approval in solid tumors and also the first approval for a tumor-infiltrating lymphocyte-based therapy.